CompletedNot Applicable

The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Turkey (Türkiye)500 participantsStarted 2020-03-01

Plain-language summary

Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common. In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of COVID 19 disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with amylase and lipase levels measured during covid-19 disease with or without pneumonia Exclusion Criteria: * Patients with pregnancy * Patients whose amylase and lipase levels were not measured during covid 19 disease * Patients with known solid organ malignacy * Patients with known hematologic malignacy

What they're measuring

to compare presence of fever in patients with and without pancreatic injury

Timeframe: 3 month

to compare presence of dyspnea in patients with and without pancreatic injury

Timeframe: 3 month

To compare cRP levels in patients with and without pancreatic injury

Timeframe: 3 month

To compare d-dimer levels in patients with and without pancreatic injury

Timeframe: 3 month

Trial details

NCT IDNCT04433754

SponsorUşak University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-06-11

View on ClinicalTrials.gov More Pancreatitis trials